- Home
- CDNA vs CLVT Comparison
CDNA vs CLVT Comparison
Compare CDNA & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDNA | CLVT |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | 12000 |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CDNA | CLVT |
|---|---|---|
| Price | $37.52 | $1.94 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $28.00 | $3.22 |
| AVG Volume (30 Days) | 1.1M | ★ 9.1M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | $2.12 |
| P/E Ratio | $752.20 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $11.26 | $1.66 |
| 52 Week High | $40.47 | $4.77 |
Technical Indicators
Market Signals| Indicator | CDNA | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 74.21 | 39.08 |
| Support Level | $15.89 | $1.90 |
| Resistance Level | $40.47 | $2.65 |
| Average True Range (ATR) | 1.65 | 0.17 |
| MACD | 0.56 | -0.03 |
| Stochastic Oscillator | 84.19 | 21.67 |
Price Performance
Historical ComparisonAbout CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.